1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Muscle Wasting Disorders – Pipeline Review, H1 2013

Muscle Wasting Disorders – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 141 pages

Muscle Wasting Disorders – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Muscle Wasting Disorders - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Muscle Wasting Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Muscle Wasting Disorders. Muscle Wasting Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Muscle Wasting Disorders.
- A review of the Muscle Wasting Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Muscle Wasting Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Muscle Wasting Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Muscle Wasting Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Muscle Wasting Disorders - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Muscle Wasting Disorders Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Muscle Wasting Disorders 12
Muscle Wasting Disorders Therapeutics under Development by Companies 14
Muscle Wasting Disorders Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Discovery and Pre-Clinical Stage Products 21
Comparative Analysis 21
Muscle Wasting Disorders Therapeutics - Products under Development by Companies 22
Muscle Wasting Disorders Therapeutics - Products under Investigation by Universities/Institutes 25
Companies Involved in Muscle Wasting Disorders Therapeutics Development 26
Amgen Inc. 26
Eli Lilly and Company 27
GlaxoSmithKline plc 28
BioLineRx, Ltd. 29
Novartis AG 30
Aphios Corporation 31
GTx, Inc. 32
Rigel Pharmaceuticals, Inc. 33
AEterna Zentaris Inc. 34
Ligand Pharmaceuticals Incorporated 35
Calzada Limited 36
Palatin Technologies, Inc. 37
Cytokinetics, Inc 38
Santhera Pharmaceuticals Holding AG 39
Asubio Pharmaceuticals, Inc. 40
Helsinn Healthcare S.A. 41
AnaptysBio, Inc. 42
Alder Biopharmaceuticals Inc. 43
KangLaiTe USA 44
Fate Therapeutics, Inc. 45
Elixir Pharmaceuticals, Inc. 46
Vicus Therapeutics, LLC 47
OHR Pharmaceutical Inc. 48
Progenra, Inc. 49
XBiotech USA, Inc. 50
Acacia Pharma Ltd. 51
Rhythm Pharmaceuticals 52
Muscle Wasting Disorders - Therapeutics Assessment 53
Assessment by Monotherapy Products 53
Assessment by Combination Products 54
Assessment by Route of Administration 55
Assessment by Molecule Type 57
Drug Profiles 59
SUN-11031 - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
macimorelin - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
AMG-745 - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
enobosarm - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
RM-131 - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
BL-5040 - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
dronabinol - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
clazakizumab - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
EX-1314 - Drug Profile 72
Product Description 72
Mechanism of Action 72
RandD Progress 72
LGD-4033 - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
AOD-9604 - Drug Profile 76
Product Description 76
Mechanism of Action 76
RandD Progress 76
Kanglaite - Drug Profile 78
Product Description 78
Mechanism of Action 78
RandD Progress 78
anamorelin hydrochloride - Drug Profile 80
Product Description 80
Mechanism of Action 80
RandD Progress 80
anamorelin hydrochloride - Drug Profile 82
Product Description 82
Mechanism of Action 82
RandD Progress 82
(megestrol + formoterol) - Drug Profile 84
Product Description 84
Mechanism of Action 84
RandD Progress 84
(etodolac + propranolol) - Drug Profile 85
Product Description 85
Mechanism of Action 85
RandD Progress 85
GDF8 inhibitor - Drug Profile 87
Product Description 87
Mechanism of Action 87
RandD Progress 87
OHR/AVR-118 - Drug Profile 88
Product Description 88
Mechanism of Action 88
RandD Progress 88
(etodolac + propranolol hydrochloride) + [sorafenib] - Drug Profile 90
Product Description 90
Mechanism of Action 90
RandD Progress 90
MT-102 - Drug Profile 91
Product Description 91
Mechanism of Action 91
RandD Progress 91
LY-2495655 - Drug Profile 93
Product Description 93
Mechanism of Action 93
RandD Progress 93
CK-2066260 - Drug Profile 94
Product Description 94
Mechanism of Action 94
RandD Progress 94
FT-301 - Drug Profile 95
Product Description 95
Mechanism of Action 95
RandD Progress 95
UX-001 SA-ER - Drug Profile 96
Product Description 96
Mechanism of Action 96
RandD Progress 96
BYM-338 - Drug Profile 97
Product Description 97
Mechanism of Action 97
RandD Progress 97
Drug For Cachexia - Drug Profile 99
Product Description 99
Mechanism of Action 99
RandD Progress 99
Drug For Cancer Cachexia - Drug Profile 100
Product Description 100
Mechanism of Action 100
RandD Progress 100
ANA-012 - Drug Profile 101
Product Description 101
Mechanism of Action 101
RandD Progress 101
mirtazapine + megestrol acetate - Drug Profile 102
Product Description 102
Mechanism of Action 102
RandD Progress 102
Ghrelin Receptor Agonists - Drug Profile 103
Product Description 103
Mechanism of Action 103
RandD Progress 103
Drug Targeting PIFR - Drug Profile 104
Product Description 104
Mechanism of Action 104
RandD Progress 104
CK-2127107 - Drug Profile 105
Product Description 105
Mechanism of Action 105
RandD Progress 105
PLX-4720 - Drug Profile 106
Product Description 106
Mechanism of Action 106
RandD Progress 106
GSK-2849466 - Drug Profile 107
Product Description 107
Mechanism of Action 107
RandD Progress 107
Xilonix - Drug Profile 108
Product Description 108
Mechanism of Action 108
RandD Progress 108
SNT-207707 - Drug Profile 109
Product Description 109
Mechanism of Action 109
RandD Progress 109
SNT-209858 - Drug Profile 110
Product Description 110
Mechanism of Action 110
RandD Progress 110
Drugs For Cancer Cachexia - Drug Profile 111
Product Description 111
Mechanism of Action 111
RandD Progress 111
Drug Targeting USP19 - Drug Profile 112
Product Description 112
Mechanism of Action 112
RandD Progress 112
P-013222 - Drug Profile 113
Product Description 113
Mechanism of Action 113
RandD Progress 113
DLN-101 - Drug Profile 114
Product Description 114
Mechanism of Action 114
RandD Progress 114
Muscle Wasting Disorders Therapeutics - Drug Profile Updates 115
Muscle Wasting Disorders Therapeutics - Discontinued Products 130
Muscle Wasting Disorders Therapeutics - Dormant Products 131
Muscle Wasting Disorders - Product Development Milestones 133
Featured News and Press Releases 133
Oct 29, 2012: GTx To Continue Phase III Clinical Development Of Enobosarm For Muscle Wasting In Lung Cancer Patients Following Planned Safety Review 133
Oct 10, 2012: Ultragenyx Pharma Presents Three Abstracts Related To UX001 Sialic Acid Extended Release Tablets At 17th Annual World Muscle Society Congress 133
Oct 08, 2012: GTx To Present Scientific Poster Presentations On Enobosarm At International Society Of Geriatric Oncology 134
Oct 03, 2012: XBiotech Receives Fast Track Designation From FDA For Anti-Cachexia Drug Xilonix 135
Oct 03, 2012: XBiotech Receives Fast Track Designation From FDA For Anti-Cachexia Drug Xilonix 135
Sep 17, 2012: GTx Announces Symposium And Presentation Of Data On Muscle Wasting In Non-Small Cell Lung Cancer Patients 136
Aug 28, 2012: Aeterna Zentaris Recruits First Patient For Phase IIA Trial In Cancer Cachexia With AEZS-130 136
Jul 05, 2012: Ultragenyx Pharma Initiates Phase II Study Of UX001 In Hereditary Inclusion Body Myopathy 137
Jun 26, 2012: GTx Announces Presentations On Effect Of Enobosarm On Improving Physical Function In Cancer Patients 138
Jun 25, 2012: GTx Announces Presentation On Enobosarm's Improvement In Physical Function In Cancer Patients With Both Low And Normal Testosterone Levels 138
Appendix 140
Methodology 140
Coverage 140
Secondary Research 140
Primary Research 140
Expert Panel Validation 140
Contact Us 141
Disclaimer 141



List of Tables

Number of Products Under Development for Muscle Wasting Disorders, H1 2013 12
Products under Development for Muscle Wasting Disorders - Comparative Analysis, H1 2013 13
Number of Products under Development by Companies, H1 2013 15
Number of Products under Development by Companies, H1 2013 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2013 17
Comparative Analysis by Late Stage Development, H1 2013 18
Comparative Analysis by Mid Clinical Stage Development, H1 2013 19
Comparative Analysis by Early Clinical Stage Development, H1 2013 20
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 21
Products under Development by Companies, H1 2013 22
Products under Development by Companies, H1 2013 (Contd..1) 23
Products under Development by Companies, H1 2013 (Contd..2) 24
Products under Investigation by Universities/Institutes, H1 2013 25
Amgen Inc., H1 2013 26
Eli Lilly and Company, H1 2013 27
GlaxoSmithKline plc, H1 2013 28
BioLineRx, Ltd., H1 2013 29
Novartis AG, H1 2013 30
Aphios Corporation, H1 2013 31
GTx, Inc., H1 2013 32
Rigel Pharmaceuticals, Inc., H1 2013 33
AEterna Zentaris Inc., H1 2013 34
Ligand Pharmaceuticals Incorporated, H1 2013 35
Calzada Limited, H1 2013 36
Palatin Technologies, Inc., H1 2013 37
Cytokinetics, Inc, H1 2013 38
Santhera Pharmaceuticals Holding AG, H1 2013 39
Asubio Pharmaceuticals, Inc., H1 2013 40
Helsinn Healthcare S.A., H1 2013 41
AnaptysBio, Inc., H1 2013 42
Alder Biopharmaceuticals Inc., H1 2013 43
KangLaiTe USA, H1 2013 44
Fate Therapeutics, Inc., H1 2013 45
Elixir Pharmaceuticals, Inc., H1 2013 46
Vicus Therapeutics, LLC, H1 2013 47
OHR Pharmaceutical Inc., H1 2013 48
Progenra, Inc., H1 2013 49
XBiotech USA, Inc., H1 2013 50
Acacia Pharma Ltd., H1 2013 51
Rhythm Pharmaceuticals, H1 2013 52
Assessment by Monotherapy Products, H1 2013 53
Assessment by Combination Products, H1 2013 54
Assessment by Stage and Route of Administration, H1 2013 56
Assessment by Stage and Molecule Type, H1 2013 58
Muscle Wasting Disorders Therapeutics - Drug Profile Updates 115
Muscle Wasting Disorders Therapeutics - Discontinued Products 130
Muscle Wasting Disorders Therapeutics - Dormant Products 131
Muscle Wasting Disorders Therapeutics - Dormant Products (Contd..1) 132



List of Figures

Number of Products under Development for Muscle Wasting Disorders, H1 2013 12
Products under Development for Muscle Wasting Disorders - Comparative Analysis, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 17
Late Stage Products, H1 2013 18
Mid Clinical Stage Products, H1 2013 19
Early Clinical Stage Products, H1 2013 20
Discovery and Pre-Clinical Stage Products, H1 2013 21
Assessment by Monotherapy Products, H1 2013 53
Assessment by Combination Products, H1 2013 54
Assessment by Route of Administration, H1 2013 55
Assessment by Stage and Route of Administration, H1 2013 56
Assessment by Molecule Type, H1 2013 57
Assessment by Stage and Molecule Type, H1 2013 58

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


Download Unlimited Documents from Trusted Public Sources

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Therapy Market in Denmark - Forecast

  • December 2016
    12 pages
  • Therapy  

  • Denmark  

View report >

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.